Global Acute Myeloid Leukemia (AML) Therapeutics - Pharmaceuticals

News provided by

Apr 26, 2017, 05:13 ET

LONDON, April 26, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Acute Myeloid Leukemia (AML) Therapeutics in US$ Thousand.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Download the full report:

https://www.reportbuyer.com/product/4838514/The report profiles 69 companies including many key and niche players such as -

- AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. Download the full report:

https://www.reportbuyer.com/product/4838514/I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting LimitationsDisclaimersData Interpretation & Reporting LevelQuantitative Techniques & AnalyticsProduct Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOKA PreludeGrowing Incidence and Poor Prognosis - A Fatal Concoction Creating Significant Unmet NeedsInadequacies Marr Existing Therapeutics; Pipeline Therapies Offer HopeCurrent and Future AnalysisStandard Mode of Treatment for AML - An OverviewStandard Approved Mode of Therapy for AML by Age GroupList of FDA-Approved Chemotherapy Drugs for Treatment of AMLBallooning Elderly Population: The Vital Growth Driver for AML TherapeuticsTable 1: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)Table 2: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)Table 3: Life Expectancy at Birth in Years of People in Select Countries (2015E) (includes corresponding Graph/Chart)Table 4: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)2. MARKET DYNAMICSGrowing Interest in the Genetics of AMLTargeted Therapies Hog Limelight in AML Therapeutic PipelineSelect Major AML Therapeutics in Late-Stage Clinical DevelopmentSelect AML Therapeutics in Phase I and II Clinical DevelopmentFLT3 - The Most Advanced Natural TargetFLT3 Kinase Inhibitors in Pipeline for AMLPIM-FLT3 Combo - A Novel Approach to AML TreatmentMidostaurin - Awaits Approval as the First Targeted TherapyQuizartinib - A Second Generation FLT3 Inhibitor in Late Stage Clinical DevelopmentChemotherapy Retains Developers' Interest; Better Chemotherapies on the HorizonVyxeos - The New Standard of Care in AML Treatment?Select Benefits of Vyxeos in a Gist:Future of Vosaroxin Shrouded in UncertaintyTough Battle Lies Ahead for GuadecitabineCC-486 Eyes Maintenance Therapy MarketDrug Targeting Mutant IDH2 Enzyme Enters Pivotal TrialsImmunotherapies in Development too Show PromiseAnnamycin Shows Promise as a Second Line Therapy for AMLVolasertib - the First in Molecular Targeting Agents for AML to Advance in Clinical TrialsADCs' Clinical Trials Depict Mixed ResultsResearch Innovations/Findings in AML TherapeuticsAnti-CD98 Antibodies Offer Novel ApproachInhibition of Metabolic Enzyme in AML Pathway Identified as an Promising OptionPersonalized Vaccine Approach Invades AML Therapeutic R&DCeramide-based Therapeutic Targets Drug Resistance of AMLFructose - Potential Target for AML Therapeutics3. ACUTE MYELOID LEUKEMIA - THE DISEASE, EPIDEMIOLOGY, ETIOLOGY, SYMPTOMS, AND DIAGNOSISUnderstanding the Bone Marrow, and the Blood CellsBlood CellsWhite CellsRed CellsPlateletsCancer - The Deadly DiseaseLeukemia - A Disease of the Bone MarrowAcute LeukemiaChronic LeukemiaHistoryAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML) TypesThe FAB Classification of AMLWHO AML ClassificationAML with Certain Genetic AbnormalitiesAML with Multilineage DysplasiaAML Related to Previous Chemotherapy or RadiationAML Not Otherwise SpecifiedUndifferentiated or Biphenotypic Acute LeukemiasFocus on Select TypesNPM1 & CEBPa Mutations in AMLFLT3 Mutated AMLRAS-Activated AMLEpigenetic Mutations in AMLDNMT3 MutationsIDH-Mutated AMLEpidemiologyEtiology of AMLChemicalsRadiationSmokingPre-existing Blood DisordersGenetic FactorsAML SymptomsIncreased Bruising or BleedingRepeated or Frequent InfectionAnemiaAML DiagnosisFull Blood CountBone Marrow ExaminationOther Tests4. TREATMENT OVERVIEWChemotherapy - The First-Line Treatment for AMLInduction TherapyPost Remission or Consolidation TherapyHematopoietic Stem Cell TransplantationTreatment for Relapsed AMLMaintenanceSide-Effects of AML TreatmentEffects on Bone Marrow, Platelets, Red Cells, and White CellsOther Common Side-EffectsChanges in Smell and TasteVomiting and NauseaChanges in BowelMucositisLoss of HairLoss in FertilityEarly MenopauseFatigueBody ImageTherapies to Complement AML Medical Treatment5. DRUG APPROVALS/CLINICAL STUDIESImmune Pharmaceuticals to Commence REMAIN ™ StudyPrecient Doses First Patient in Phase 1b/2 Clinical Trial of PTX-200Stemline Therapeutics Presents Phase 2 Trial Data of SL-401Helsinn and MEI Pharma Announce Phase 2 Trial results of Pracinostat and azacitidineDaiichi Sankyo Announces Safety and Efficacy Data from Phase 1 Study of DS-3032Pfizer Reveals Positive Phase 2 Study Results of glasdegib/PF -04449913Teva's Trisenox Gains EU Approval for APLDaiichi Sankyo Begins Patient Enrollment for Phase 3 QuANTUM Trial on QuizartinibGlycoMimetics Doses First Patient in Phase 2 of GM71Seattle Genetics Initiates Phase 3 Clinical Trial for Vadastuximab TalirineImmunoGen Begins Clinical Study of IMGN779 for Treatment of AMLAgios Pharmaceuticals Initiates Phase 1/2 Study of AG-221 in Combination with VIDAZA®Bio-Path Announces Positive Phase II Results of BP1001Sunesis Secures MAA Validation from EMA for Vosaroxin in AMLAgios Pharmaceuticals Initiates Phase 1b Study of AG-221EMA Expands Indications of Celgene's VIDAZA®Astellas Pharma Doses First Patient in Phase 3 Registration Trial of ASP2215OXiGENE Initiates Phase 1b/2 Trial of OXi4503Seattle Genetics Initiates Phase 1b Clinical Trial of SGN-CD33AAgios Pharmaceuticals Announces Safety and Efficacy Data from Phase 1 Trial of AG-120MacroGenics Doses First Patient in Phase 1 Study of MGD0066. RECENT INDUSTRY ACTIVITYMacroGenics Received Orphan Drug Designation for AML Drug Candidate MGD006FDA Puts Hold on Various Phase I Vadastuximab TrialsArog Receives Orphan Drug Designation for Crenolanib in EUFDA Grants Priority Review to Novartis' NDA for PKC412Immune Pharmaceuticals Obtains FDA Assistance in Ceplene® Pivotal TrialJazz Pharmaceuticals Begins NDA Submission for Vyxeos™Celgene to File NDA for AG-221Jazz Pharmaceuticals to Acquire Celator PharmaceuticalsCelgene and Agios Enter into Collaboration with AbbottCelyad Enters into Exclusive Licensing Agreement with OnoAstex Enters into Clinical Trial Collaboration with GenentechAbbVie's venetoclax Receives Orphan Drug Designation from EMANovartis Bags Breakthrough Status for Midostaurin Therapy in AMLAbbVie Obtains Breakthrough Therapy Designation for Venetoclax with HMAs in AML TreatmentFDA Clears Hybrigenics to Carry Out Phase II Trials on inecalcitol in AML PatientsHybrigenics Gets Approval to Carry Out Phase II Trials on inecalcitol in AML Patients in FranceBoehringer and Philogen Team Up to Develop AML TherapeuticsAstex Pharmaceuticals' SG0/guadecitabine Receives Orphan Drug Designation from FDAHybrigenics Obtains Orphan Drug Designation from FDA for Inecalcitol in AML TreatmentDaiichi Sankyo to Acquire Ambit BiosciencesCelgene Takes Over Rights to Blood Cancer Drugs of AgiosKaryopharm Therapeutics' Selinexor (KPT-330) Receives Orphan Drug Designation from FDAOtsuka Buys Rights to Dacogen® from Eisai7. FOCUS ON SELECT PLAYERSAbbVie Inc. (USA)Actinium Pharmaceuticals, Inc. (USA)Agios Pharmaceuticals, Inc. (USA)Amgen Inc. (USA)Astellas Pharma Inc. (Japan)Astex Pharmaceuticals, Inc. (USA)Celgene Corporation (USA)CTI BioPharma Corp. (USA)Cyclacel Pharmaceuticals, Inc. (USA)Daiichi Sankyo Company Limited (Japan)F. Hoffmann-La Roche AG (Switzerland)Immune Pharmaceuticals Inc. (USA)Janssen-Cilag Limited (UK)Jazz Pharmaceuticals plc (Ireland)MEI Pharma, Inc. (USA)Merus N.V. (The Netherlands)Novartis AG (Switzerland)Pfizer Inc. (USA)Seattle Genetics, Inc. (USA)Stemline Therapeutics, Inc. (USA)Sunesis Pharmaceuticals, Inc. (USA)Tolero Pharmaceuticals, Inc. (USA)8. GLOBAL MARKET PERSPECTIVETable 5: World Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 6: World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 7: World 14-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATESA.Market AnalysisCurrent & Future AnalysisRising Elderly Population: Key Growth DriverTable 8: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage Share of Overall Population (includes corresponding Graph/Chart)Table 9: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)A Peek into Incidence and Mortality Statistics of AMLTable 10: New Cases of Leukemia in the US by Type: 2017E (includes corresponding Graph/Chart)Table 11: Incidence and Mortality of AML in the US by Gender: 2017E (includes corresponding Graph/Chart)Low Survival Rates Create Huge Unmet Need for TherapeuticsTable 12: 5-Year Survival Rate of Various Leukemias in the US (2016) - Survival Rate Percentage for Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Chronic Lymphoblastic Leukemia (CLL) (includes corresponding Graph/Chart)Table 13: 5-Year Survival Rates (%) of Various Pediatric Cancers in the US (1975-79 & 2003-2009) - Survival Rates of Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Lymphomas and Reticuloendothelial Neoplasms (includes corresponding Graph/Chart)Robust R&D Activity Hint at Better ProspectsProduct Approvals/Clinical StudiesStrategic Corporate DevelopmentsKey PlayersB.Market AnalyticsTable 14: US Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 15: US Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)2. CANADAA.Market AnalysisCurrent & Future AnalysisAging Population and Rising Incidence Drives GrowthTable 16: Aging Population in Canada (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage Share of Overall PopulationB.Market AnalyticsTable 17: Canadian Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 18: Canadian Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)3. JAPANA.Market AnalysisCurrent & Future AnalysisAging Population Drives Market GrowthTable 19: Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage Share of Overall Population (includes corresponding Graph/Chart)Product Approvals/Clinical TrialsStrategic Corporate DevelopmentsKey PlayersB.Market AnalyticsTable 20: Japanese Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 21: Japanese Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)4. EUROPEA.Market AnalysisCurrent & Future AnalysisChanging Demographics to Propel Market GrowthTable 22: European Population By Age Group (2013, 2020 & 2040): Percentage Share Breakdown of Age Groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart)Product Approvals/Clinical TrialsStrategic Corporate DevelopmentB.Market AnalyticsTable 23: European Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 24: European Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 25: European 14-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of European Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

A.Market Analysis

Current & Future Analysis

Strategic Corporate Development

B.Market Analytics

Table 26: French Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 27: French Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANYA.Market AnalysisCurrent & Future AnalysisStrategic Corporate DevelopmentB.Market AnalyticsTable 28: German Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 29: German Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

Market Analysis

Table 30: Italian Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 31: Italian Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOMA.Market AnalysisCurrent & Future AnalysisTable 32: Aging Population in the United Kingdom (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)Key PlayerB.Market AnalyticsTable 33: UK Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 34: UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

A.Market Analysis

Current & Future Analysis

Clinical Trial Development

Strategic Corporate Development

Key Players

B.Market Analytics

Table 35: Rest of Europe Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 36: Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. REST OF WORLDA.Market AnalysisCurrent & Future AnalysisFocus on Select Regional MarketsChinaGreying Population Offers Opportunity for Growth in ChinaTable 37: Aging Population in China (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)IndiaA Note on Incidence of Leukemias in IndiaLow Treatment Rates - A Hurdle to Market GrowthIncreasing Share of Elderly in Population Uncovers OpportunitiesTable 38: Aging Population in India (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)Medical Tourism - A Shot in the Arm for AML Therapeutics MarketClinical Trial DevelopmentB.Market AnalyticsTable 39: Rest of World Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 40: Rest of World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 73) The United States (40) Canada (3) Japan (3) Europe (24) - France (3) - Germany (2) - The United Kingdom (5) - Spain (1) - Rest of Europe (13) Asia-Pacific (Excluding Japan) (1) Middle East (2)Download the full report: